JP6302733B2 - 腸管バリア機能亢進剤、腸疾患治療及び予防用医薬組成物 - Google Patents
腸管バリア機能亢進剤、腸疾患治療及び予防用医薬組成物 Download PDFInfo
- Publication number
- JP6302733B2 JP6302733B2 JP2014088832A JP2014088832A JP6302733B2 JP 6302733 B2 JP6302733 B2 JP 6302733B2 JP 2014088832 A JP2014088832 A JP 2014088832A JP 2014088832 A JP2014088832 A JP 2014088832A JP 6302733 B2 JP6302733 B2 JP 6302733B2
- Authority
- JP
- Japan
- Prior art keywords
- isomaltomegalosaccharide
- intestinal
- pharmaceutical composition
- barrier function
- intestinal barrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 27
- 230000007358 intestinal barrier function Effects 0.000 title claims description 23
- 208000028774 intestinal disease Diseases 0.000 title claims description 14
- 210000005027 intestinal barrier Anatomy 0.000 title claims description 9
- 230000002265 prevention Effects 0.000 title description 5
- 239000004480 active ingredient Substances 0.000 claims description 12
- 230000009471 action Effects 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000003623 enhancer Substances 0.000 claims description 7
- 230000002708 enhancing effect Effects 0.000 claims description 7
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 4
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 4
- 229930182470 glycoside Natural products 0.000 claims description 4
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N quercetin Natural products C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 4
- 229960001285 quercetin Drugs 0.000 claims description 4
- 235000005875 quercetin Nutrition 0.000 claims description 4
- -1 quercetin glycoside Chemical class 0.000 claims description 4
- 102000000591 Tight Junction Proteins Human genes 0.000 description 17
- 108010002321 Tight Junction Proteins Proteins 0.000 description 17
- 210000001578 tight junction Anatomy 0.000 description 16
- 238000006116 polymerization reaction Methods 0.000 description 12
- 125000004122 cyclic group Chemical group 0.000 description 11
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 9
- 230000002496 gastric effect Effects 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 8
- 230000004888 barrier function Effects 0.000 description 6
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 229920002307 Dextran Polymers 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229920000310 Alpha glucan Polymers 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 230000004890 epithelial barrier function Effects 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- 150000004666 short chain fatty acids Chemical class 0.000 description 3
- 108010012023 Dextrin dextranase Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 235000021391 short chain fatty acids Nutrition 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 238000002834 transmittance Methods 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004887 epithelial permeability Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
さらに本発明は、イソマルトメガロ糖を有効成分として含有する腸疾患治療用医薬組成物に関する。
加えて本発明は、イソマルトメガロ糖を有効成分として含有する腸疾患予防用医薬組成物に関する。
本発明の腸管バリア機能亢進剤、腸疾患治療用医薬組成物及び腸疾患予防用医薬組成物においては、前記イソマルトメガロ糖は直鎖タイプのイソマルトメガロ糖であることが効果の観点で好ましい。
[方法]
7週齢のSprague Dawley系雄性ラットを5日間馴化飼育後、麻酔下で管腔内を洗浄し、15cmの空腸結紮ループを作成した。ループ内にはTJ透過マーカーとしてLucifer yellow(LY)とFITC-dextranを添加した試験液(対照)、これに3-4%(W/V)の環状または直鎖状のイソマルトオリゴ糖ないし、環状または直鎖状のイソマルトメガロ糖を添加した試験液を注入し、20分後放血屠殺した。その後直ちに腸ループ内容液、およびループに残存したマーカーを粘膜とともに回収、LYとFITCの蛍光強度を測定し、それぞれの透過率を求めてTJのバリア機能を評価した。用いた糖の平均重合度は、環状タイプのイソマルトオリゴ糖(Oligo):7.9、イソマルトメガロ糖(Megalo):10.3、直鎖タイプのイソマルトオリゴ糖(Oligo):3.3、イソマルトメガロ糖(Megalo):12.6である。
直鎖と環状のどちらのイソマルトメガロ糖でも、対照群(Control)と比較してLY(図1、図3)、FITC(図2、図4)ともに透過率が低下した。またその作用は、直鎖タイプでより強い傾向が見られた。一方、イソマルトオリゴ糖では、環状タイプLYを除いて対照群との有意差は見られなかった。これらの結果より、イソマルトメガロ糖は空腸上皮のTJを介したバリア機能を高めること、その作用は糖の鎖長に依存することが示唆された。
Claims (9)
- イソマルトメガロ糖を腸管バリア機能亢進作用の有効成分として含有する腸管バリア機能亢進剤。
- 前記イソマルトメガロ糖が直鎖タイプのイソマルトメガロ糖である請求項1に記載の腸管バリア機能亢進剤。
- イソマルトメガロ糖とケルセチン配糖体とを含む腸管バリア機能亢進剤を除く、請求項1または2に記載の腸管バリア機能亢進剤。
- イソマルトメガロ糖を腸管バリア機能亢進作用の有効成分として含有する腸疾患治療用医薬組成物。
- 前記イソマルトメガロ糖が直鎖タイプのイソマルトメガロ糖である請求項4に記載の腸疾患治療用医薬組成物。
- イソマルトメガロ糖とケルセチン配糖体とを含む腸疾患治療用医薬組成物を除く、請求項4または5に記載の腸疾患治療用医薬組成物。
- イソマルトメガロ糖を腸管バリア機能亢進作用の有効成分として含有する腸疾患予防用医薬組成物。
- 前記イソマルトメガロ糖が直鎖タイプのイソマルトメガロ糖である請求項7に記載の腸疾患予防用医薬組成物。
- イソマルトメガロ糖とケルセチン配糖体とを含む腸疾患予防用医薬組成物を除く、請求項7または8に記載の腸疾患予防用医薬組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014088832A JP6302733B2 (ja) | 2014-04-23 | 2014-04-23 | 腸管バリア機能亢進剤、腸疾患治療及び予防用医薬組成物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014088832A JP6302733B2 (ja) | 2014-04-23 | 2014-04-23 | 腸管バリア機能亢進剤、腸疾患治療及び予防用医薬組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015205856A JP2015205856A (ja) | 2015-11-19 |
JP6302733B2 true JP6302733B2 (ja) | 2018-03-28 |
Family
ID=54603019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014088832A Active JP6302733B2 (ja) | 2014-04-23 | 2014-04-23 | 腸管バリア機能亢進剤、腸疾患治療及び予防用医薬組成物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6302733B2 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6417061B1 (ja) | 2018-02-20 | 2018-10-31 | 国立大学法人北海道大学 | α−1,6−グルコシル転移活性を有する酵素 |
JP6650546B1 (ja) | 2019-08-01 | 2020-02-19 | 日本食品化工株式会社 | α−1,6−グルコシル転移反応を触媒する活性を有するタンパク質 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011178764A (ja) * | 2010-03-04 | 2011-09-15 | Ajinomoto Co Inc | 腸内ビフィズス菌増殖促進剤および腸管バリア機能改善剤 |
-
2014
- 2014-04-23 JP JP2014088832A patent/JP6302733B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2015205856A (ja) | 2015-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shafabakhsh et al. | Chitosan: A compound for drug delivery system in gastric cancer-a review | |
Wüpper et al. | Cyclodextrins, natural compounds, and plant bioactives—a nutritional perspective | |
Leclercq | Interactions between cyclodextrins and cellular components: Towards greener medical applications? | |
Kurkov et al. | Cyclodextrins | |
AU2010221209B2 (en) | Microencapsulated bioactive agents for oral delivery and methods of use thereof | |
Choukaife et al. | Current advances in chitosan nanoparticles based oral drug delivery for colorectal cancer treatment | |
EP2616046B1 (en) | Aqueous drug delivery system comprising off-flavor masking agent | |
KR20050046776A (ko) | 유도체화된 사이클로덱스트린으로 안정화한 수성 충전조성물을 포함하는 캅셀 | |
Uekama et al. | Pharmaceutical uses of cyclodextrin derivatives | |
Asal et al. | Controlled synthesis of in-situ gold nanoparticles onto chitosan functionalized PLGA nanoparticles for oral insulin delivery | |
Das et al. | Neutralization of cholera toxin with nanoparticle decoys for treatment of cholera | |
RU2736245C2 (ru) | Оромукозальные фармацевтические препараты с высокой биодоступностью на основе циклодекстрина и сукралозы | |
JP6302733B2 (ja) | 腸管バリア機能亢進剤、腸疾患治療及び予防用医薬組成物 | |
WO2001041757A1 (fr) | Composition pharmaceutique contenant de la cyclodextrine | |
CN102099011A (zh) | 基质载体组合物、方法及用途 | |
JPWO2002088246A1 (ja) | プルラン高含有成形物とその製造方法並びにその用途 | |
CN114466658A (zh) | 口服递送的治疗性组合物和其用途 | |
Chadha et al. | Inulin as a delivery vehicle for targeting colon-specific cancer | |
EP3089744A1 (en) | Racecadotril liquid compositions | |
JP3597239B2 (ja) | 安定な点眼剤 | |
Wang et al. | Amelioration of Acute Alcoholic Liver Injury via Attenuating Oxidative Damage and Modulating Inflammation by Means of Ursodeoxycholic Acid–Zein Nanoparticles | |
Jalali et al. | Enhancing effect of bile salts on gastrointestinal absorption of insulin | |
Aldawsari et al. | Combined use of cyclodextrins and hydroxypropylmethylcellulose stearoxy ether (Sangelose®) for the preparation of orally disintegrating tablets of type-2 antidiabetes agent glimepiride | |
Zheng et al. | Controlled bioactive compound delivery systems based on double polysaccharide film-coated microparticles for liquid products and their release behaviors | |
Tomita et al. | Nonlinear intestinal absorption of (1→ 3)-β-D-glucan caused by absorptive and secretory transporting system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170315 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170315 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171114 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171219 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180227 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180305 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6302733 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |